Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis-Reference-Cited by-同舟云学术

Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis

Published:2014-12-09 Issue:2 Volume:42 Page:129-139
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:J Dermatol

Author:

Murata Yoko¹,Song Michael²,Kikuchi Hisayuki¹,Hisamichi Katsuya¹,Xu Xie L.³,Greenspan Andrew⁴,Kato Mai¹,Chiou Chiun-Fang⁵,Kato Takeshi¹,Guzzo Cynthia⁴,Thurmond Robin L.³,Ohtsuki Mamitaro⁶,Furue Masutaka⁷

Affiliation:

1. Research & Development; Janssen Pharmaceutical KK; Tokyo Japan

2. Immunology; Janssen Research & Development; LLC; Spring House PA USA

3. Immunology; Janssen Research & Development; LLC; San Diego CA USA

4. Medical Affairs; Janssen Scientific Affairs; LLC; Horsham PA USA

5. Patient Reported Outcomes; Janssen Global Services; LLC; Raritan NJ USA

6. Department of Dermatology; Jichi Medical University; Tochigi Japan

7. Department of Dermatology; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

Funder

Janssen Pharmaceutical K. K.

Publisher

Wiley